ADVISORY, Dec. 19, 2017 --
What:
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Roger Crystal, M.D., Chief Executive Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Wednesday, December 20, 2017 – 9:15 a.m. to 9:30 a.m. ET
Opiant Media Contact:
Scott Schneider
[email protected]
Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



